FDA Approves AFINITOR — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's Afinitor (Everolimus) for Oncology Treatment Novartis Pharmaceuticals Corporation received FDA approval for Afinitor (everolimus), an oral mTOR inhibitor that is expected to establish a new treatment category in advanced cancer management and drive significant revenue growth in the company's oncology portfolio. The approval positions Novartis to capture market share in the growing precision medicine segment while potentially establishing everolimus as a standard-of-care option across multiple tumor types.